WDNA250117P12000
- 0.00
- 0.000.00%
WISDOMTREE BIOREVOLUTION FUND Newsroom
U.S. stocks closed higher | The three major Indexes collectively rose, with the Nasdaq increasing by nearly 1%; chip stocks surged, with Broadcom and Taiwan Semiconductor rising over 5%, and NVIDIA increasing nearly 4%.
① The Nasdaq China Golden Dragon Index rose by 0.91%; ② The PHLX Semiconductor Index rose by over 3%; ③ MicroStrategy purchased 5,262 Bitcoins; ④ The suspect in the UnitedHealth executive's murder case pleaded not guilty.
Ely Lilly Shares Are Trading Higher After the FDA Approved the Company's Zepbound, a Weight Loss Drug Designed to Treat Moderate-to-severe Obstructive Sleep Apnea in Adults With Obesity.
Eli Lilly Stock Is Rising Monday: What's Going On?
ResMed, Inspire Medical Fall After Lilly's Zepbound Gains Sleep Apnea Indication
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
Materials, Software Stocks Are Best Poised for H1 Outperformance: Goldman Sachs
Eli Lilly's Zepbound Receives FDA Approval For Obesity-Linked Sleep Apnea Drug
Musk causes a commotion at Capitol Hill, is a "Trump 2.0" prototype emerging?
Analysis suggests that Musk's recent act of detonating a political nuclear bomb may be a rehearsal for the Trump 2.0 era of Musk's action model, intended to exert pressure on Congress. However, some also say that the consensus at Mar-a-Lago is that Musk has proven to be an effective Weapon to pressure Congress and a scapegoat for any backlash.
Eli Lilly and Co's Zepbound has been approved by the FDA for the treatment of obstructive sleep apnea.
① The FDA in the USA approved Eli Lilly and Co's weight loss medication Zepbound on Friday for the treatment of obstructive sleep apnea (OSA), making it the first drug approved for directly treating this common sleep disorder; ② The active ingredient in Zepbound is Tirzepatide, which was initially used to treat type 2 diabetes, namely Eli Lilly and Co's Mounjaro.
Trending Stocks in Bearish Pre-holiday Week for U.S. Stock Market
Novo Nordisk Raises Expectations for Eli Lilly After CagriSema Slipup
Did Novo-Nordisk A/S fall, leaving Eli Lilly and Co to dominate the weight loss medication market?
Novo-Nordisk A/S faced a "Waterloo," with new drug effects falling short of expectations, causing a dramatic drop in stock prices. The landscape of the weight loss drug market is quietly changing; will Eli Lilly and Co become a sole oligopoly?
Pfizer Gets FDA Accelerated Approval for Braftovi
EXCLUSIVE: Weight-Loss Market Experts Scoop Up Novo Nordisk Stock After Worst Drop Since 2002 Following Drug Trial Miss
J.P. Morgan's Top Healthcare Stocks for 2025
Benzinga Market Summary: Novo Nordisk Falls On Weight Loss Data, Shares Of Competitor Lilly Rise, S&P Continues Higher
US Stock Preview | USA PCE data overall underperformed expectations, and the declines in the three major futures indices significantly narrowed; US stocks face another test: the largest "Triple Witching" day in history arrives tonight!
The latest weight loss drug's phase 3 trial results were below expectations, resulting in Novo-Nordisk A/S's shares dropping nearly 20% in Pre-Market Trading; the Trump Media Technology Group's shares fell over 4% in Pre-Market Trading as Trump transferred all his shares to a revocable REITs.
Novo Nordisk's Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges
The weight loss effect of the new drug was below expectations, and Novo-Nordisk A/S saw its stock plummet by 28% in Pre-Market Trading, while competitor Eli Lilly and Co surged over 12%.
The experimental results show that patients who received subcutaneous injections of CagriSema lost an average of 22.7% of their weight after 68 weeks. If volunteers who dropped out of the trial are included, the average weight loss effect decreases to 20.4%, both below the company's previous expectation of 25%.
Novo Nordisk New Obesity Therapy CagriSema Outperforms Semaglutide in Phase 3 Trial